Loading…
Loading…
Investors need to pay close attention to ACT stock based on the movements in the options market lately.
SEATTLE, Aug. 19, 2026 /PRNewswire/ -- ACT Capital Advisors, a premier investment bank serving founder-led and privately held companies, is pleased to announce the successful acquisition of its client, Advanced Marketing Group, LLC ("AMG"), by StoneX Commodity Solutions LLC, a subsidiary of StoneX Group Inc. ("StoneX": NASDAQ: SNEX). ACT Capital Advisors Managing Directors Stephen Spencer and Ron Huff, along with Associate Zack Hsieh, served as advisors to AMG on the transaction.
LONDON, Ontario, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc . (“Aduro” or the “Company”) (Nasdaq: ADUR) (TSX: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced the selection of Saipem S.p.A.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Enact Holdings, Inc. (ACT) Q2 2026 Earnings Call Transcript
Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $1.15 per share a year ago.
GAAP Net Income of $175 million , or $1.25 per diluted share Adjusted Operating Income of $177 million , or $1.26 per diluted share Return on Equity of 13.0% and Adjusted Operating Return on Equity of 13.2% Primary Insurance in-force of $274 billion , a 2% year-over-year increase PMIERs Sufficiency of 161% or approximately $1.9 billion Book Value Per Share of $39.06 and Book Value Per Share excluding AOCI of $39.66 Increased Full-Year Capital Return Guidance to be between $550 million and $600 million
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.